At a glance: Sermorelin is a lab-made copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It prompts the pituitary gland to release the body's own growth hormone. It was FDA-approved as Geref for children with growth hormone deficiency and for pituitary testing, then discontinued in 2008 for business reasons, not safety. Today it is sold as a compounded prescription, mostly by anti-aging clinics. Evidence for anti-aging, muscle or fat-loss benefits in healthy adults is limited to small, older studies, and it is banned in sport.
What is sermorelin?
Sermorelin (also called GHRH 1-29) is a synthetic peptide made of the first 29 amino acids of growth hormone-releasing hormone, a natural hormone made in the hypothalamus. This short piece is the part of the hormone that does the work.
FDA approved it as Geref Diagnostic in 1990, to test whether the pituitary can release growth hormone, and as Geref in 1997, to treat children with idiopathic growth hormone deficiency and slow growth. Manufacturer EMD Serono discontinued both in 2008. In 2013, FDA formally determined they were not withdrawn for safety or effectiveness reasons.
How does sermorelin work?
- Stimulates the pituitary: it binds GHRH receptors on the pituitary gland, which then releases growth hormone
- Raises IGF-1: growth hormone signals the liver to make IGF-1, which drives many of growth hormone's effects on muscle, bone and fat
- Keeps natural rhythms: unlike injected growth hormone, it works through the body's own system, so release stays pulsed and is still limited by the brake hormone somatostatin
- Needs a working pituitary: it cannot help if the pituitary itself cannot make growth hormone
Supporters argue that this built-in feedback makes it safer than taking growth hormone directly. That idea is plausible but has not been tested in long-term trials.
What the research shows
| Use | Evidence | Bottom line |
|---|---|---|
| Children with growth hormone deficiency | Controlled trials supporting 1997 FDA approval | Increased growth rate; approved until the product was discontinued |
| Pituitary function testing | FDA-approved diagnostic use from 1990 | Established, but no longer marketed |
| Healthy older adults | Small 1990s studies, typically a few dozen people over months | Raised IGF-1 toward young-adult levels; small changes in lean mass, skin and well-being; never replicated at scale |
| Adult growth hormone decline (review, Walker 2006) | Expert commentary | Argued it may be a safer approach than growth hormone; no long-term trial has tested this |
| Muscle, fat loss, cognition, longevity | No randomized trials of sermorelin | Claims are extrapolated from growth hormone research or testimonials |
For comparison, a 2007 systematic review of growth hormone itself in healthy older adults found about 2 kg more lean mass and 2 kg less fat, but no improvement in strength, fitness or bone density, along with more side effects.
Why it gets attention
- Anti-aging clinics: marketed as a gentler way to restore youthful growth hormone levels
- Body composition and recovery: promoted for muscle, fat loss, sleep and exercise recovery
- Legal availability: unlike many peptides, it was once FDA-approved and is widely compounded with a prescription
- Blends: often compared with or combined with other growth hormone secretagogues such as ipamorelin and CJC-1295
How it is used
Sermorelin is given as an injection under the skin, prescribed by a clinician and prepared by a compounding pharmacy. Some pharmacies also make tablets that dissolve in the mouth, which have not been studied the way the injection was. The original approved dose was for children; no dose is approved for adults. This page does not provide dosing guidance.
What about side effects?
From the Mayo Clinic drug information and original labeling:
- Common: pain, redness or swelling at the injection site
- Less common: headache, flushing, dizziness, sleepiness, hyperactivity or trouble sitting still
- Rare: itching, hives and trouble swallowing, which may signal an allergic reaction and need prompt care
- Thyroid: an underactive thyroid can blunt its effect
Long-term, raising growth hormone and IGF-1 may carry the risks seen with growth hormone itself: fluid retention, joint pain, carpal tunnel symptoms and worse blood sugar control. Higher IGF-1 has been linked to some cancers in observational studies, though not proven to cause them. Compounded products are not FDA-reviewed for quality, and online "research" versions may be mislabeled or contaminated.
Regulatory status
- Previously FDA-approved (Geref, 1990 and 1997); discontinued in 2008 for business reasons. FDA's 2013 finding that this was not for safety or effectiveness means generic versions could be approved in the future, though none is marketed.
- No approved product is sold in the US today. Sermorelin is available as a compounded prescription, which is not FDA-reviewed for safety, effectiveness or quality.
- No FDA-approved use in adults, including anti-aging, weight loss or performance.
- Prohibited in sport by the World Anti-Doping Agency, because it raises growth hormone.
Sermorelin vs growth hormone
| Sermorelin | Growth hormone (somatropin) | |
|---|---|---|
| How it works | Signals the pituitary to release its own growth hormone | Replaces growth hormone directly |
| Feedback limits | Preserved (pulsed release, somatostatin brake) | Bypassed |
| Requires working pituitary | Yes | No |
| US status | Discontinued brand; compounded only | FDA-approved for specific deficiencies |
The bottom line
Sermorelin has a real medical history: it was an approved treatment for children with growth hormone deficiency, and it left the market for business, not safety, reasons. That history makes it one of the more legitimate peptides sold today. But the anti-aging claims rest on small studies from the 1990s and on theory, and even growth hormone itself has shown limited benefits for healthy older adults. Anyone considering it should have growth hormone and IGF-1 properly tested and talk with an endocrinologist.
Frequently asked questions
What is Sermorelin?
The first 29 amino acids of growth-hormone-releasing hormone, the active part of the natural hormone.
How is Sermorelin taken?
Subcutaneous injection (when marketed).
Is Sermorelin FDA approved?
Was FDA-approved; the maker discontinued it in 2008.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about Sermorelin?
- Growth in children with growth hormone deficiency.
- Growth hormone levels in older adults.
What side effects have been reported?
- Injection site reactions (redness, pain, swelling)
- Flushing
- Headache
- Dizziness
- A metallic taste
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. Sermorelin has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- Mayo Clinic: Sermorelin (injection route), description, precautions and side effects. View source
- Federal Register: Determination that GEREF (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness (March 2013). View source
- USADA: What should athletes know about sermorelin? View source
- Acibadem International: Sermorelin, what it is, what it is not, and what clinics rarely say (evidence review). View source
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006. View source